We are proud to announce that CardiaMetrics has successfully completed its second fundraising round, securing €1.7 million in new investment to fuel the next phase of our development. This milestone reflects growing confidence in our vision to transform the management of heart failure through advanced remote monitoring technologies — and signals a strong step forward in our journey since our first successful €300K seed round in 2024.
Building on Our Early Progress
A little over a year ago, we shared the exciting news of our first funding round, in which we raised €300,000 from private investors and leading cardiologists who recognized the unique value of our solution for bridging the gap between non-invasive telemonitoring approaches and implantable pressure sensors.
That funding enabled us to lay strong foundations — accelerating key strategic hires and preparing our first clinical studies in collaboration with the Caen University Hospital (CHU de Caen) to validate clinical safety and kick off our AI strategy.
Today, with €2M raised, we are ready to accelerate even further.
What This Funding Enables
This latest round will support several high-impact strategic pillars:
Accelerated Clinical Development
We have expanded our clinical efforts, launching our first human clinical trial — a key milestone in generating robust evidence and demonstrating the real-world performance of our monitoring solution.
Innovation and AI Integration
Further investment will fuel our AI pipeline, allowing us to transform physiological signals into early, actionable digital biomarkers that support clinicians in anticipating cardiac decompensations before they become critical.
Team Expansion & Industrial Scaling
Our team has grown significantly to meet the technical, clinical, and regulatory demands of bringing a medical device to market. This includes bolstering our engineering, clinical research, and regulatory teams to deliver on our roadmap.
Strategic Advisory & Ecosystem Engagement
We have also established a Strategic Advisory Committee, bringing together experienced clinicians and industry leaders to guide our clinical strategy and reinforce our market positioning moving forward.
Strengthening Our Vision and Market Opportunity
Since our first fundraising announcement, CardiaMetrics has continued to assert its position in the heart failure telemonitoring landscape by combining cutting-edge sensing technologies, AI capabilities, and a deep clinical partnership model (10 clinical centers will onboard in our next clinical study). This new funding reflects investor confidence in our mission to provide clinically relevant, home-based telemetry that meaningfully impacts patient care.
With heart failure affecting millions worldwide and health systems seeking solutions that both improve outcomes and optimize costs, CardiaMetrics is uniquely positioned to help shift care paradigms from reactive to proactive, preventive strategies.
What’s Next
We remain deeply committed to our clinical milestones, regulatory pathway, and expansion goals — with ambitious plans to scale our solution across Europe and USA.
Stay tuned as we continue to publish updates on our clinical progress, scientific collaborations, and technology development throughout 2026 and beyond.